Division of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Department of Cardiology, The Texas Heart Institute, Houston, TX, USA.
J Cardiovasc Transl Res. 2024 Aug;17(4):935-945. doi: 10.1007/s12265-024-10501-1. Epub 2024 Feb 26.
In-hospital mortality associated with cardiogenic shock (CS) remains high despite the use of percutaneous assist devices. We sought to determine whether support with VA-ECMO or Impella in patients with CS alters specific components of the plasma proteome. Plasma samples were collected before device implantation and 72 h after initiation of support in 11 CS patients receiving ECMO or Impella. SOMAscan was used to detect 1305 circulating proteins. Sixty-seven proteins were changed after ECMO (18 upregulated and 49 downregulated, p < 0.05), 38 after Impella (10 upregulated and 28 downregulated, p < 0.05), and only eight proteins were commonly affected. Despite minimal protein overlap, both devices were associated with markers of reduced inflammation and increased apoptosis of inflammatory cells. In summary, ECMO and Impella are associated with reduced expression of inflammatory markers and increased markers of inflammatory cell death. These circulating proteins may serve as novel targets of therapy or biomarkers to tailor AMCS use.
尽管使用了经皮辅助装置,与心源性休克(CS)相关的住院死亡率仍然很高。我们试图确定 VA-ECMO 或 Impella 在 CS 患者中的支持是否改变了血浆蛋白质组的特定成分。在接受 ECMO 或 Impella 治疗的 11 例 CS 患者中,在装置植入前和支持开始后 72 小时收集血浆样本。使用 SOMAscan 检测 1305 种循环蛋白。ECMO 后有 67 种蛋白发生变化(18 种上调,49 种下调,p<0.05),Impella 后有 38 种蛋白发生变化(10 种上调,28 种下调,p<0.05),只有 8 种蛋白共同受到影响。尽管蛋白质重叠最小,但两种设备都与炎症反应减轻和炎症细胞凋亡增加的标志物相关。总之,ECMO 和 Impella 与炎症标志物表达减少和炎症细胞死亡标志物增加有关。这些循环蛋白可能成为治疗的新靶点或生物标志物,以调整 AMCS 的使用。